Illumina said this week that it plans this year to submit for US Food and Drug Administration clearance its HiSeq 2500 platform coupled with Verinata Health's Verifi test for noninvasive prenatal fetal aneuploidy screening.

In a presentation at the JP Morgan Healthcare conference in San Francisco, President and CEO Jay Flatley said the company plans to file the instrument for clearance in 2014 and that the Verifi test would be the first assay. Clearance of the HiSeq 2500 would enable other third parties to submit their test on the system, he said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.